Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | SELE | P16581 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | ATF4 | P18848 | 7/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19810305 | 0.85 | MEN1 (0.52) | MEN1KMT2AKIF11CHEK2SLC6A4 | |
| SCHEMBL23819693 | 0.83 | CHRNA3 (0.50) | KMT2ACHRNA3PPARGPPARAICAM1 | |
| SCHEMBL23753577 | 0.82 | MEN1 (0.57) | MEN1KMT2ACHRNA3PPARGPPARA | |
| SCHEMBL5265818 | 0.82 | MEN1 (0.57) | MEN1KMT2AKIF11 | |
| SCHEMBL30063441 | 0.82 | MEN1 (0.57) | MEN1KMT2AKIF11 | |
| SCHEMBL3331532 | 0.81 | CHRNA3 (0.49) | MEN1KMT2ACHRNA3PPARGPPARA | |
| SCHEMBL4311410 | 0.79 | MEN1 (0.53) | MEN1KMT2AKIF11 | |
| SCHEMBL27511537 | 0.79 | MEN1 (0.53) | MEN1KMT2AKIF11 | |
| SCHEMBL28688992 | 0.79 | MEN1 (0.53) | MEN1KMT2AKIF11 | |
| SCHEMBL28890049 | 0.79 | MEN1 (0.53) | MEN1KMT2AKIF11CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109310675-A | Therapeutic inhibiting compound | 莱福斯希医药公司 | 2019-02-05 | — | — | CN | claimed |
| CN-116917293-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-113474348-A | Substituted oxopyridine derivatives | 拜耳公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210253528-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| CN-110804061-B | Pyrazole and pyrazine formamide compound containing cyclopropyl segment and application thereof | 中国医学科学院医药生物技术研究所 | 2021-01-05 | — | — | CN | disclosed |
| CN-110804061-A | Pyrazole and pyrazine formamide compound containing cyclopropyl segment and application thereof | 中国医学科学院医药生物技术研究所 | 2020-02-18 | — | — | CN | disclosed |
| CN-106103414-B | Substituted benzamides for arthropod processing | 拜耳作物科学股份公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-109310675-A | Therapeutic inhibiting compound | 莱福斯希医药公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-108617166-A | Protein Kinase Inhibitor Benzolactam Compounds | 大冢制药株式会社 | 2018-10-02 | — | — | CN | disclosed |
| CN-108290881-A | Therapeutic compounds and methods of use thereof | 健泰科生物技术公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-107849022-A | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | 亚瑞克西斯制药公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-104797555-B | N-substituted benzamides and methods of use thereof | 基因泰克公司 | 2017-12-22 | — | — | CN | disclosed |
| CN-106488910-A | Inhibitors of kras g12c | 亚瑞克西斯制药公司 | 2017-03-08 | — | — | CN | disclosed |
| CN-106232582-A | Aryl and heteroaryl ether compound as ROR gamma modulators | 格兰马克药品股份有限公司 | 2016-12-14 | — | — | CN | disclosed |
| CN-105934255-A | Combination therapy comprising an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer | 美国安进公司 | 2016-09-07 | — | — | CN | disclosed |
| CN-104797555-A | N-substituted benzamides and methods of use thereof | GENENTECH INC | 2015-07-22 | — | — | CN | disclosed |
| CN-101970420-B | Oxadiazole derivatives | MERCK SERONO SA | 2014-09-24 | — | — | CN | disclosed |
| CN-101472888-B | Optically pure flavone derivatives for treating proliferative disorders and process for preparing same | PIRAMAL LIFE SCIENCES LTD | 2014-02-26 | — | — | CN | disclosed |
| EP-1740551-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253528-A1 | CHEMICAL COMPOUNDS | ATF4, EIF2AK4, ATF1 | MEN1 3941/4885KMT2A 4235/4885CHRNA3 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.